- Home
- BTI vs SNY Comparison
BTI vs SNY Comparison
Compare BTI & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BTI
- SNY
- Stock Information
- Founded
- BTI 1902
- SNY 1994
- Country
- BTI United Kingdom
- SNY France
- Employees
- BTI N/A
- SNY N/A
- Industry
- BTI Medicinal Chemicals and Botanical Products
- SNY Biotechnology: Pharmaceutical Preparations
- Sector
- BTI Health Care
- SNY Health Care
- Exchange
- BTI Nasdaq
- SNY Nasdaq
- Market Cap
- BTI 97.7B
- SNY 116.5B
- IPO Year
- BTI N/A
- SNY N/A
- Fundamental
- Price
- BTI $47.92
- SNY $48.47
- Analyst Decision
- BTI Strong Buy
- SNY Buy
- Analyst Count
- BTI 1
- SNY 2
- Target Price
- BTI N/A
- SNY $62.50
- AVG Volume (30 Days)
- BTI 6.3M
- SNY 2.1M
- Earning Date
- BTI 02-13-2025
- SNY 07-24-2025
- Dividend Yield
- BTI 6.17%
- SNY 3.31%
- EPS Growth
- BTI N/A
- SNY 39.56
- EPS
- BTI 1.70
- SNY 5.45
- Revenue
- BTI $32,383,539,681.00
- SNY $48,817,552,946.00
- Revenue This Year
- BTI $1.68
- SNY $3.39
- Revenue Next Year
- BTI $2.92
- SNY $7.05
- P/E Ratio
- BTI $28.58
- SNY $8.86
- Revenue Growth
- BTI N/A
- SNY N/A
- 52 Week Low
- BTI $31.50
- SNY $45.80
- 52 Week High
- BTI $49.58
- SNY $60.12
- Technical
- Relative Strength Index (RSI)
- BTI 56.29
- SNY 43.47
- Support Level
- BTI $46.38
- SNY $47.64
- Resistance Level
- BTI $48.84
- SNY $49.37
- Average True Range (ATR)
- BTI 0.55
- SNY 0.61
- MACD
- BTI -0.19
- SNY 0.12
- Stochastic Oscillator
- BTI 54.72
- SNY 46.15
About BTI British American Tobacco Industries p.l.c. ADR
The second-largest tobacco company by volume, British American Tobacco sold 505 billion cigarettes in 2024. Its leading brands are Dunhill, Kent, Pall Mall, Lucky Strike, and Rothmans in cigarettes. Its ownership of the Camel, Natural American Spirit, and Newport brands are limited to the us. In next-generation products, the company has the Vuse brand in vaping, Glo in heated tobacco, and Velo in modern oral tobacco. The company also owns a 25.5% stake in ITC limited, the largest Indian cigarette company.
About SNY Sanofi ADS
Sanofi develops and markets drugs with a concentration in vaccines, immunology, oncology, cardiovascular disease, diabetes, and over-the-counter treatments. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing about 30% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.